Mizuho raised the firm’s price target on Verastem (VSTM) to $15 from $14 and keeps an Outperform rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Is VSTM a Buy, Before Earnings?
- Verastem Reports Promising Phase 1/2a Trial Data
- Verastem announces encouraging data from ongoing phase 1/2a of VS-7375 dose
- Buy Rating Affirmed for Verastem’s VS-7375 Due to Promising Efficacy and Competitive Edge in KRAS G12D Inhibitors
- Verastem data ‘best-in-class’ despite slight decline, says RBC Capital